The US FDA’s Center for Drug Evaluation and Research produced two novels approvals, for Cara Therapeutics, Inc.’s Korsuva and Ascendis Pharma A/S’s Skytrofa, after the Center for Biologics Evaluation and Research opened last week with the highly publicized full approval of Pfizer Inc./BioNTech SE’s COVID-19 vaccine Comirnaty.
In oncology, however, the biggest news was a withdrawal, not an approval, as Genentech, Inc.’s Tecentriq lopped a “dangling”...





